| 產(chǎn)品名稱 |
HCC1428 |
| 商品貨號 |
B164558 |
| Organism |
Homo sapiens, human |
| Tissue |
mammary gland/breast; derived from metastatic site: adenocarcinoma and pleural effusion |
| Cell Type |
Epithelial |
| Product Format |
frozen |
| Morphology |
epithelial |
| Culture Properties |
adherent; large epithelial cells with occasional vacuole formation |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
TNM stage IV, grade 4, adenocarcinoma |
| Age |
49 years |
| Gender |
female |
| Ethnicity |
Caucasian, White |
| Storage Conditions |
liquid nitrogen vapor phase |
| Karyotype |
polyploid |
| Derivation |
HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene. This cell line was initiated on 11/4/95 and took 15 months to establish. |
| Clinical Data |
female
Caucasian, White
49 years
There is a family history of breast cancer (maternal grandmother). |
| Oncogene |
her2/neu -, p53 - |
| Genes Expressed |
HCC1428 cells are positive for the expression of Epithelial glycoprotein 2 [EGP2]; cytokeratin 19 The cells are negative for expression of Her2-neu and for expression of p53. |
| Comments |
An EBV transformed lymphoblastoid cell line [HCC1428 BL] from the same patient is available as ATCC CRL-2328. The homozygous deletion in the FHIT gene is retained in the lymphoblastoid line.
The FHIT gene, which spans the FRA3B fragile site at chromosome 3p14.2, is a candidate tumor suppressor gene in breast and other cancers. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
- Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
- Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37°C
Subculture Ratio: 1:4 to 1:8
Medium Renewal: Every 2 to 3 days.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994.
|
| Cryopreservation |
Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
| STR Profile |
CSF1PO: 10 D13S317: 12 D16S539: 12,8 D5S818: 11,12 D7S820: 9 THO1: 8 TPOX: 8 vWA: 17 |
| Name of Depositor |
AF Gazdar, AK Virmani |
| Year of Origin |
November 4, 1995 |
| References |
Ahmadian M, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57: 3664-3668, 1997. PubMed: 9288768
Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771
|
